AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 4135024 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated randomly
Number of subjects: 0
Study 799990 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg nitrazepam
Number of subjects: 434
Study 799990 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg temazepam
Number of subjects: 434
Study 31433781 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vitamin C and omega-3 polyunsaturated fatty acids (n-3 PUFA) given the day before surgery and for the first 5 days post-operation.
Number of subjects: 160
Study 31433781 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group receiving no active treatment.
Number of subjects: 160
Study 29210875 — intervention group
Group type: EXPERIMENTAL
Intervention: Benson muscle relaxation
Number of subjects: 105
Study 29210875 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature sounds
Number of subjects: 105
Study 29210875 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 105
Study 26924732 — intervention group
Group type: EXPERIMENTAL
Intervention: ULMbET
Number of subjects: 1648
Study 26924732 — intervention group
Group type: COMPARATOR
Intervention: TA-UGET
Number of subjects: 1648
Study 25198068 — intervention group
Group type: EXPERIMENTAL
Intervention: Devon Active Villages intervention providing 12 weeks of physical activity opportunities for all age groups, with at least three different types of activities per village.
Number of subjects: 10412
Study 25198068 — intervention group
Group type: EXPERIMENTAL
Intervention: Devon Active Villages intervention
Number of subjects: 10412
Study 25198068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 10412
Study 22282373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (3 μg/kg) administered intravenously twice daily for 1 week with cisplatin
Number of subjects: 42
Study 22282373 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) administered twice daily for 1 week with cisplatin
Number of subjects: 42
Study 21171525 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringerfundin infusion
Number of subjects: 0
Study 21171525 — intervention group
Group type: COMPARATOR
Intervention: Plasma-Lyte infusion
Number of subjects: 0
Study 18156664 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 9
Study 18156664 — intervention group
Group type: COMPARATOR
Intervention: CHO beverage
Number of subjects: 9
Study 18156664 — intervention group
Group type: COMPARATOR
Intervention: PLAC beverage
Number of subjects: 9
Study 15834591 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Rating Index (FRI)
Number of subjects: 131
Study 15834591 — intervention group
Group type: COMPARATOR
Intervention: Oswestry questionnaire
Number of subjects: 131
Study 12422433 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative interviews regarding patient perceptions of information disclosure during recruitment and throughout the study.
Number of subjects: 7
Study 9814085 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic dietary fibre supplementation (doubled from 17.5 g/day to 34.4 g/day)
Number of subjects: 5
Study 9814085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of fibre supplementation
Number of subjects: 5
Study 8129764 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 148
Study 8129764 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-2R level
Number of subjects: 148
Study 2912326 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination aerosol of 100 micrograms beclomethasone dipropionate and 200 micrograms salbutamol, administered four times a day for 4 weeks.
Number of subjects: 57
Study 2912326 — intervention group
Group type: COMPARATOR
Intervention: Doubling the standard dose of salbutamol (400 micrograms), administered four times a day for 4 weeks.
Number of subjects: 57
Study 1056054 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (stress condition with distracting noises)
Number of subjects: 120
Study 1056054 — intervention group
Group type: COMPARATOR
Intervention: Control group (no stress)
Number of subjects: 120
Study 31664968 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed yoga
Number of subjects: 0
Study 31664968 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-informed drumming
Number of subjects: 0
Study 31664968 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 0
Study 31664968 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 28251555 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (1-2 post-tetanic counts)
Number of subjects: 127
Study 28251555 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular blockade (train-of-four ratio 10%)
Number of subjects: 127
Study 28251555 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard insufflation pressure (12 mmHg)
Number of subjects: 127
Study 28251555 — intervention group
Group type: COMPARATOR
Intervention: Low insufflation pressure (8 mmHg)
Number of subjects: 127
Study 25344632 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct volume
Number of subjects: 46
Study 25344632 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct volume alone
Number of subjects: 46
Study 25344632 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct volume adjusted for race, systolic blood pressure, and NIHSS
Number of subjects: 46
Study 25344632 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct volume cut point of 6.8 cm(3)
Number of subjects: 46
Study 25344632 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct volume greater than 3 cm(3)
Number of subjects: 46
Study 24733799 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxepin oral rinse
Number of subjects: 155
Study 24733799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 23014494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers supplemented with 2 doses of 200,000 iu retinol (n = 13)
Number of subjects: 34
Study 23014494 — intervention group
Group type: COMPARATOR
Intervention: Mothers nonsupplemented (n = 19)
Number of subjects: 34
Study 23014494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups of mothers
Number of subjects: 34
Study 23014494 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants' VA intake from breast milk
Number of subjects: 34
Study 23014494 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants' VA liver stores assessed by MRDR test
Number of subjects: 34
Study 23014494 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma retinol
Number of subjects: 34
Study 19542901 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alpha 20 mg/kg biweekly
Number of subjects: 18
Study 19542901 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alpha 40 mg/kg biweekly
Number of subjects: 18
Study 19542901 — intervention group
Group type: EXPERIMENTAL
Intervention: Alglucosidase alpha treatment
Number of subjects: 18
Study 17103488 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatin (Creon)
Number of subjects: 80
Study 17103488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 15119162 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at point Neiguan (PC 6)
Number of subjects: 0
Study 15119162 — intervention group
Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 0
Study 15119162 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 0
Study 15119162 — intervention group
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Number of subjects: 0
Study 11329522 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality care for depression (QI interventions)
Number of subjects: 1104
Study 11329522 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1104
Study 9413463 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir 1000 mg three times a day
Number of subjects: 304
Study 9413463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304
Study 8215283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole
Number of subjects: 337
Study 8215283 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 337
Study 8215283 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole and Albendazole
Number of subjects: 337
Study 2824623 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 X 10(4) units of human leukocyte interferon/kg of body weight for 12 doses over 14 days (total, approximately 3.6 X 10(7) units)
Number of subjects: 34
Study 2824623 — intervention group
Group type: COMPARATOR
Intervention: Placebo in equivalent volumes
Number of subjects: 34
Study 31991284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 22
Study 31991284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 30362226 — intervention group
Group type: EXPERIMENTAL
Intervention: Neck cooling device
Number of subjects: 65
Study 30362226 — intervention group
Group type: COMPARATOR
Intervention: No neck cooling device (control)
Number of subjects: 65
Study 28512158 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only
Number of subjects: 243
Study 28512158 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus diet
Number of subjects: 243
Study 28512158 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body fat
Number of subjects: 243
Study 28512158 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous abdominal fat
Number of subjects: 243
Study 28512158 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal fat change
Number of subjects: 243
Study 26244299 — intervention group
Group type: EXPERIMENTAL
Intervention: OCT angiography
Number of subjects: 24
Study 26244299 — intervention group
Group type: COMPARATOR
Intervention: Fluorescein angiography (FA)
Number of subjects: 24
Study 26244299 — intervention group
Group type: COMPARATOR
Intervention: Indocyanine green angiography (ICGA)
Number of subjects: 24
Study 23939297 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthiest tertile of modified Alternate Healthy Eating Index (mAHEI) score
Number of subjects: 6213
Study 23939297 — intervention group
Group type: EXPERIMENTAL
Intervention: More than 3 servings of fruits per week
Number of subjects: 6213
Study 23939297 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest tertile of total and animal protein intake
Number of subjects: 6213
Study 23939297 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake
Number of subjects: 6213
Study 23939297 — intervention group
Group type: COMPARATOR
Intervention: Sodium intake
Number of subjects: 6213
Study 23939297 — intervention group
Group type: COMPARATOR
Intervention: Normal protein intake
Number of subjects: 6213
Study 20535539 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (maximum dose of 10 mg for 3 months)
Number of subjects: 22
Study 20535539 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for 3 months)
Number of subjects: 22
Study 18322413 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-G regimen (doxorubicin and ifosfamide)
Number of subjects: 27
Study 18322413 — intervention group
Group type: EXPERIMENTAL
Intervention: EIA regimen (etoposide, ifosfamide and doxorubicin)
Number of subjects: 27
Study 18322413 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease in standardized uptake value (SUV; responders)
Number of subjects: 27
Study 18322413 — intervention group
Group type: COMPARATOR
Intervention: Increase or stable SUV (non-responders)
Number of subjects: 27
Study 17184489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (1.2 g/day)
Number of subjects: 5375
Study 17184489 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (4.0 g/day)
Number of subjects: 5375
Study 17184489 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5375
Study 12750137 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative drain for 24 hours (12 patients)
Number of subjects: 21
Study 12750137 — intervention group
Group type: COMPARATOR
Intervention: No drain (9 patients)
Number of subjects: 21
Study 10756221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory agents (specific agents not mentioned)
Number of subjects: 1041
Study 10756221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1041
Study 10756221 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1041
Study 9058221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 MAC desflurane
Number of subjects: 60
Study 9058221 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 MAC isoflurane
Number of subjects: 60
Study 9058221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 MAC desflurane
Number of subjects: 60
Study 9058221 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 MAC isoflurane
Number of subjects: 60
Study 9058221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anesthetic agent)
Number of subjects: 60
Study 8334749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestagen (500 micrograms/day of Promegestone for 21 days out of a 28-day cycle)
Number of subjects: 35
Study 8334749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 8334749 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestagen
Number of subjects: 35
Study 3555163 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous bupivacaine epidural analgesia
Number of subjects: 30
Study 27283375 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise with blood flow restriction (BFR) at 20% of one repetition maximum (1RM)
Number of subjects: 18
Study 27283375 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional high‐intensity resistance exercise at 65% of 1RM
Number of subjects: 18
Study 27257857 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered pain management program (Pain Course)
Number of subjects: 463
Study 25522380 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose reduction intervention (removal of one antipsychotic medication each week, reducing dose by 0 to 50 chlorpromazine equivalents)
Number of subjects: 163
Study 25522380 — intervention group
Group type: COMPARATOR
Intervention: Observation group (no intervention)
Number of subjects: 163
Study 23312053 — intervention group
Group type: EXPERIMENTAL
Intervention: OM-3 FFA (Epanova)
Number of subjects: 54
Study 23312053 — intervention group
Group type: COMPARATOR
Intervention: OM-3 EE (Lovaza)
Number of subjects: 54
Study 20589465 — intervention group
Group type: EXPERIMENTAL
Intervention: Wholesome, nutritionally balanced mid day meal (MDM) provided by an NGO
Number of subjects: 221
Study 20589465 — intervention group
Group type: COMPARATOR
Intervention: Locally prepared MDM by village panchayats
Number of subjects: 221
Study 18705806 — intervention group
Group type: EXPERIMENTAL
Intervention: Z250 composite
Number of subjects: 12
Study 18705806 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom composite
Number of subjects: 12
Study 18705806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji IX glass‐ionomer cement
Number of subjects: 12
Study 18705806 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitremer resin‐modified glass‐ionomer
Number of subjects: 12
Study 18705806 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% sucrose solution
Number of subjects: 12
Study 18705806 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control group)
Number of subjects: 12
Study 16444905 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 15 mg/kg/day
Number of subjects: 58
Study 16444905 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef 30 mg/kg/day
Number of subjects: 58
Study 11434164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome acute phase
Number of subjects: 37
Study 11434164 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotic syndrome remission phase
Number of subjects: 37
Study 11434164 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 9717017 — intervention group
Group type: EXPERIMENTAL
Intervention: Single plane two-dimensional echocardiograms
Number of subjects: 371
Study 9717017 — intervention group
Group type: COMPARATOR
Intervention: Biplane Simpson's method
Number of subjects: 371
Study 8281693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol (EE), 35 micrograms, intravenous administration
Number of subjects: 33
Study 8281693 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 33
Study 2688360 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day of TISACID (acid‐neutralizing capacity = 78 mmol)
Number of subjects: 332
Study 2688360 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g/day of TISACID (acid‐neutralizing capacity = 156 mmol)
Number of subjects: 332
Study 2688360 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 g/day of TISACID (acid‐neutralizing capacity = 312 mmol)
Number of subjects: 332
Study 2688360 — intervention group
Group type: COMPARATOR
Intervention: 1.0 g/day cimetidine (HISTODIL)
Number of subjects: 332
Study 19473593 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 45 mg (PIO45)
Number of subjects: 60
Study 19473593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 372777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 71
Study 372777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 30700178 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate removal of urinary catheter (0h)
Number of subjects: 221
Study 30700178 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate removal of urinary catheter (6h)
Number of subjects: 221
Study 30700178 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed removal of urinary catheter (24h)
Number of subjects: 221
Study 30700178 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of urinary catheter (0h)
Number of subjects: 221
Study 28913703 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized literacy instruction supported by A2i technology
Number of subjects: 0
Study 28913703 — intervention group
Group type: COMPARATOR
Intervention: Traditional instruction
Number of subjects: 0
Study 29110698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate radiographer report of GP CXR
Number of subjects: 0
Study 29110698 — intervention group
Group type: COMPARATOR
Intervention: Standard radiographer GP CXR reporting
Number of subjects: 0
Study 29110698 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reporting of GP CXRs
Number of subjects: 0
Study 26049689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem)
Number of subjects: 156
Study 26049689 — intervention group
Group type: COMPARATOR
Intervention: Observation (obs)
Number of subjects: 156
Study 26049689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem) with high hENT1 expression
Number of subjects: 156
Study 26049689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem) with low hENT1 expression
Number of subjects: 156
Study 26049689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine (gem) with no hENT1 expression
Number of subjects: 156
Study 26049689 — intervention group
Group type: COMPARATOR
Intervention: Observation (obs) with high hENT1 expression
Number of subjects: 156
Study 26049689 — intervention group
Group type: COMPARATOR
Intervention: Observation (obs) with low hENT1 expression
Number of subjects: 156
Study 26049689 — intervention group
Group type: COMPARATOR
Intervention: Observation (obs) with no hENT1 expression
Number of subjects: 156
Study 24120952 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate psychodynamic psychotherapy for 12 weeks
Number of subjects: 15
Study 24120952 — intervention group
Group type: COMPARATOR
Intervention: Delayed psychodynamic psychotherapy after 3 months
Number of subjects: 15
Study 22020354 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 80 mg/d
Number of subjects: 718
Study 22020354 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 30 mg/d
Number of subjects: 718
Study 22020354 — intervention group
Group type: EXPERIMENTAL
Intervention: Casopitant 120 mg/d
Number of subjects: 718
Study 22020354 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg/d
Number of subjects: 718
Study 22020354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 718
Study 19410509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300mg, 450mg, and 600mg daily
Number of subjects: 1493
Study 19410509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 450mg and 600mg
Number of subjects: 1493
Study 19410509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 1493
Study 19410509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1493
Study 17406926 — intervention group
Group type: EXPERIMENTAL
Intervention: Interesterified palm oil (IPO)
Number of subjects: 38
Study 17406926 — intervention group
Group type: COMPARATOR
Intervention: Native palm oil (NPO)
Number of subjects: 38
Study 17406926 — intervention group
Group type: COMPARATOR
Intervention: High-oleic sunflower oil (HOS)
Number of subjects: 38
Study 17406926 — intervention group
Group type: EXPERIMENTAL
Intervention: All test meals
Number of subjects: 38
Study 15545560 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior 90 degrees partial fundoplication
Number of subjects: 112
Study 15545560 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 112
Study 15545560 — intervention group
Group type: COMPARATOR
Intervention: Both procedures
Number of subjects: 112
Study 11169968 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence in women under 25 years
Number of subjects: 1340
Study 11169968 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence in women aged 35-44 years
Number of subjects: 1340
Study 11169968 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA prevalence in women aged 65 years and older
Number of subjects: 1340
Study 11169968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-associated HPV types
Number of subjects: 1340
Study 11169968 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cancer-associated HPV types
Number of subjects: 1340